Reporting the first successful treatment with oral Isavuconazole as primary antifungal agent following debridement, in an immunocompromised adult male with acute invasive fungal sinusitis involving multiple simultaneous fungal species. His comorbidities were retroviral and COVID infections, uncontrolled diabetes, ketoacidosis, and renal failure. A two-year follow-up revealed no recurrence.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11890808 | PMC |
| http://dx.doi.org/10.1007/s12070-024-05247-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Successful Primary Oral Isavuconazole Therapy in Acute Invasive Fungal Sinusitis with Triple Fungal Species and Multiple Comorbidities.
Indian J Otolaryngol Head Neck Surg
February 2025
Department of Pathology, Naruvi Hospitals, Vellore, India.
Reporting the first successful treatment with oral Isavuconazole as primary antifungal agent following debridement, in an immunocompromised adult male with acute invasive fungal sinusitis involving multiple simultaneous fungal species. His comorbidities were retroviral and COVID infections, uncontrolled diabetes, ketoacidosis, and renal failure. A two-year follow-up revealed no recurrence.
View Article and Find Full Text PDFChanges in the blood cyclosporine level after switching from voriconazole to isavuconazole in a patient with aplastic anemia: insights from physiologically based pharmacokinetic model simulation and the Adverse Event Reporting System database study.
Front Microbiol
February 2025
Department of Pharmacy, Mie University Hospital, Mie, Japan.
Introduction: Isavuconazole, a broad-spectrum triazole approved by the United States Food and Drug Administration (FDA) in 2015, moderately inhibits cytochrome P450 3A4. Although antifungal agents are often used concomitantly with cyclosporine, the effect of switching from voriconazole to isavuconazole on the blood cyclosporine level remains unclear.
Case: A 63-year-old Japanese male was administered oral cyclosporine (10:00 and 21:00) for severe aplastic anemia.
Assessment of the Effective Dose of Isavuconazole, Itraconazole, Posaconazole, and Voriconazole to Achieve Goal Serum Concentrations in Pediatric Patients at a Single Center.
J Pediatr Pharmacol Ther
February 2025
Department of Pharmacy (LKM, GL, LMD), Mayo Clinic, Division of Pediatric Infectious Diseases, Department of Pediatric and Adolescent Medicine (EHR), Mayo Clinic, Department of Quantitative Health Sciences (KCM), Mayo Clinic, Rochester, MN.
Objective: The optimal dose for triazoles in pediatric patients may substantially vary given the dynamic changes in pharmacokinetics and pharmacodynamics, based on disease severity. Therapeutic drug monitoring has been a valuable tool to help guide management and avoid potential toxicities associated with treatment of invasive fungal infections (IFIs). Goal azole serum concentrations are based on specific drug, indication, and minimum inhibitory concentration when known.
View Article and Find Full Text PDFSuccessful Management of Rhino-Orbital Mucormycosis in a Diabetic Patient: A Case Report.
Cureus
January 2025
Internal Medicine, Centro Hospitalar Universitário Lisboa Central - Hospital de São José, Lisbon, PRT.
Mucormycosis is a rare but aggressive fungal infection, primarily affecting immunocompromised patients, with diabetes being a significant risk factor. This report describes the case of a 20-year-old male with poorly controlled type 1 diabetes who presented with facial swelling, proptosis, and necrotic nasal lesions. Imaging and biopsy confirmed rhino-orbital mucormycosis with .
View Article and Find Full Text PDFUse of isavuconazole in mucormycosis: a systematic review.
BMC Infect Dis
January 2025
Department of Microbiology Faculty of Medicine and Allied Sciences, Rajarata University of Sri Lanka, Saliyapura Sri Lanka, 50008, Sri Lanka.
Background: Mucormycosis is an opportunistic fungal infection which is associated with poor prognosis. Only a few antifungals are available in the arsenal against mucormycosis. The global guidelines for diagnosing and managing mucormycosis recommend high doses of liposomal amphotericin B (LAmB) as the first-line treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!